| Literature DB >> 29998874 |
Binamra Basnet1, Aditya Bhushan1, Rehan Khan2, Guresh Kumar3, Vinod Kumar Sharma1, Alpana Sharma2, Somesh Gupta1.
Abstract
Background & objectives: Vitiligo is an acquired skin disease characterized by depigmented areas of the skin. Increased release of catecholamines from autonomic nerve endings in microenvironment of melanocytes in affected skin might be involved in the aetiopathogenesis of vitiligo. Levels of catecholamines are considered as being related to onset or worsening of the disease. Therefore, in this study, the role of catecholamines was evaluated in mapping disease stability and outcome of vitiligo patients undergoing melanocyte transfer.Entities:
Keywords: Dopamine - epinephrine - melanocyte transfer - norepinephrine - vanillylmandelic acid - vitiligo
Mesh:
Substances:
Year: 2018 PMID: 29998874 PMCID: PMC6057259 DOI: 10.4103/ijmr.IJMR_657_16
Source DB: PubMed Journal: Indian J Med Res ISSN: 0971-5916 Impact factor: 2.375
Clinical characteristics of vitiligo patients and the control individuals
Fig. 1Number of responders and non-responders in three different clinically determined stability groups. Group 1, < three months < one year; Group 2, ≥ one year < two years; Group 3, ≥ three years.
Comparison of plasma and urinary catecholamine and vanillylmandelic acid (VMA) levels between pre- and post-intervention values in patients and healthy controls
Comparison of values of plasma and urinary catecholamine and vanillylmandelic acid (VMA) between pre- and post-intervention of responders and non-responders
Fig. 2Pre- and post-intervention levels of urinary VMA in responders, non-responders and healthy controls. VMA, vanillylmandelic acid; RPrI, responder pre-intervention; RPoI, responder post-intervention; NRPrI, non-responder pre-intervention; NRPoI, non-responder post-intervention; HC, healthy controls. *P<0.05 compared to healthy controls.